Generics

Latest News


CME Content


A December 9 hearing of the U.S. Senate Special Committee on Aging had senators looking closely at several possible solutions to the recent, massive price spikes for particular generic drugs, including having FDA speed approval for competitors for products with no competition.

U.S. Senators Amy Klobuchar (D-Minn.) and Chuck Grassley (R-Iowa) recently reintroduced legislation that would make it illegal for brand-name drug manufacturers to pay-off other drug manufacturers to keep generic versions of brand-name drugs off the market.

That’s the allegation made in a potential class action lawsuit that claims CVS deliberately overcharged some customers for generic drugs by submitting claims to their insurance companies at inflated prices.

Four generic manufacturers (Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals, and Torrent Pharmaceuticals) received the go-ahead April 28 to market their generic versions for Abilify for the treatment of schizophrenia and bipolar disorder.

The Food and Drug Administration (FDA) has released its lists of approved biosimilar licensed products, called the “Purple Book”. The invaluable site includes the date a biological product was licensed under the PHS Act and whether FDA evaluated the biological product for reference product exclusivity.

As healthcare facilities across the nation deal with shortages of certain drugs, including generics, pharmacists and pharmacy managers are tasked with the daily monitoring of drug supplies and increased communications with other healthcare professionals such as nurses and physicians.

Camber Pharmaceuticals

Camber Pharmaceuticals strives to be the most reliable and cost effective generic pharmaceutical supplier across a broad range of therapeutic classes.